NYSE - Nasdaq Real Time Price USD

Ginkgo Bioworks Holdings, Inc. (DNA)

Compare
7.75 +0.13 (+1.71%)
At close: November 1 at 4:00 PM EDT
7.90 +0.15 (+1.94%)
After hours: November 1 at 6:53 PM EDT
Loading Chart for DNA
DELL
  • Previous Close 7.62
  • Open 7.74
  • Bid 7.68 x 1200
  • Ask 7.90 x 900
  • Day's Range 7.65 - 7.98
  • 52 Week Range 5.26 - 75.20
  • Volume 434,373
  • Avg. Volume 1,391,030
  • Market Cap (intraday) 430.709M
  • Beta (5Y Monthly) 1.10
  • PE Ratio (TTM) --
  • EPS (TTM) -18.00
  • Earnings Date Aug 8, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 8.80

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

www.ginkgobioworks.com

1,218

Full Time Employees

December 31

Fiscal Year Ends

Recent News: DNA

View More

Performance Overview: DNA

Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

DNA
88.54%
S&P 500
20.10%

1-Year Return

DNA
85.86%
S&P 500
36.60%

3-Year Return

DNA
98.60%
S&P 500
24.39%

5-Year Return

DNA
98.17%
S&P 500
37.60%

Compare To: DNA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DNA

View More

Valuation Measures

Annual
As of 11/1/2024
  • Market Cap

    430.71M

  • Enterprise Value

    152.61M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.10

  • Price/Book (mrq)

    0.52

  • Enterprise Value/Revenue

    0.83

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -22.30%

  • Return on Equity (ttm)

    -76.83%

  • Revenue (ttm)

    184.34M

  • Net Income Avi to Common (ttm)

    -897.68M

  • Diluted EPS (ttm)

    -18.00

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    730.37M

  • Total Debt/Equity (mrq)

    54.29%

  • Levered Free Cash Flow (ttm)

    -167.4M

Research Analysis: DNA

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 56.21M
Earnings -217.18M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

7.00 Low
8.80 Average
7.75 Current
10.00 High
 

Company Insights: DNA

People Also Watch